lebrikizumab
eli lilly
['lebri', 'advocate 1', 'lebri,(-celebri)']
interesting that the 4 weekly lebrikizumab was similar to 2 weekly dosing for #eczema in early responders in the advocate 1 and 2 at 1 year from andrew blauvelt notable for around 13-14% conjunctivitis ae too #eadvcongress 
@OfficialUoM Clinical Senior Lecturer in #Dermatology #RxEpi
working on #Psoriasis @BADBIR @PsoProtect 
@BrJDermatol Associate Editor for Guidelines